[Statins and gastrointestinal cancers]

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Context:

• Statins, widely used for cholesterol management, have demonstrated antitumour effects in preclinical models of gastrointestinal cancers.
• The precise chemopreventive mechanisms of statins, including their role in oxidative stress, autophagy, and cell signaling, are not fully elucidated.
• Clinical trial results have largely failed to corroborate the promising findings from experimental studies.

Purpose:

• To review and synthesize existing literature on the chemopreventive effects of statins in various gastrointestinal cancers.
• To evaluate the efficacy of different statin types (hydrophilic vs. hydrophobic) and dosages in cancer chemoprevention.
• To identify gaps in current knowledge and suggest future research directions.

Summary:

• Preclinical studies suggest statins possess antitumour properties against gastrointestinal cancers through mechanisms like enhanced oxidative stress and altered cell proliferation.
• Clinical trial data indicate that standard daily statin doses (10-20 mg) have minimal to no significant antitumour effect.
• Hydrophobic statins may exhibit a more pronounced chemopreventive effect compared to hydrophilic statins, though more data is needed for higher doses (30-40 mg).

Impact:

• Current evidence suggests statins are not a substitute for established oncological screening or surveillance methods.
• Chemoprevention with statins cannot be considered standard medical practice for gastrointestinal cancers at this time.
• Further long-term studies, including subgroup analyses based on statin compound and dosage, are required to determine their definitive role in gastrointestinal cancer prevention.